Is acƟve surveillance (AS) a trustworthy and viable method to manage prostate cancer in a variety of pracƟce seƫngs -that is, outside the small group of academic centers that have pioneered and proven the approach in North America? The answer appears to be yes -in the short run at least, according to findings from a nine-site cohort study that includes a veterans administraƟon (VA) hospital and a community-based pracƟce. The study was published in the February issue of The Journal of Urology (Vol. 95, pp. 313-320, 2016). "AS is safe and a good iniƟal strategy. About 10% to 15% of men fall off each year and transiƟon to treatment," summarized invesƟgator Daniel Lin, MD, a urologist at the University of Washington and Veterans Affairs Puget Sound Health Care System in SeaƩle, WA. This VA center is parƟcipaƟng in the Canary Prostate AS Study (PASS), the only mulƟcenter study of AS in North America. Other sites include the Eastern Virginia Medical School in Norfolk, VA, which has a higher percentage of black paƟents than the other eight study sites. The cohort study involves 905 men with very-low-, low-, and intermediate-risk prostate cancer (according to NaƟonal Comprehensive Cancer Network [NCCN] definiƟons) who were enrolled from 2008 to 2013. Although median follow-up is only 28 months, there have been no prostate-cancer-specific deaths in the cohort, and only two men who transiƟoned to surgery were found to have posiƟve lymph nodes. Of the 905 parƟcipants, 216 (24%) underwent tumor grade
In a surprising study result, the use of intermiƩent androgen-deprivaƟon therapy (iADT) for prostate cancer is not associated with fewer long-term adverse events than conƟnuous ADT (cADT). The outcome was unexpected because it was hypothesized that the intermiƩent schedule, which gives paƟents a break from treatment, would be less harmful. ADT is associated with an array of adverse events, including sexual dysfuncƟon, bone demineralizaƟon, cardiovascular disease, metabolic complicaƟons, cogniƟve changes, and diminished quality of life. In this study of men with metastaƟc disease -the first to look at longterm health issues -there was a significantly increased One year ago, German researchers published a singlecenter study of 4,752 men with prostate cancer that showed an association between the use of erectile dysfunction (ED) drugs (after radical prostatectomy [RP] ) and biochemical recurrence (BCR). The drugs, known as phosphodiesterase type 5 inhibitors (PDE5i), are a firstline treatment for the ED that commonly occurs after RP. "The study made quite a splash," said Stacy Loeb, MD, a urologist at New York University in New York City, who was not involved with the German research. She told Medscape that some clinicians had a subsequent "hesitaƟon" to use these drugs because of "concern that the finding was real." Last year, the German researchers said they were "astonished" by the link between the use of a PDE5i and BCR aŌer RP. They had theorized that the ED drugs would be protecƟve. In their new study, Dr. Loeb and a team of internaƟonal researchers decided to take another look at the issue. But they used bigger, more authoritaƟve data sources from Editor's Note: Us TOO invites certain physicians and others to provide informaƟon and commentary for the Hot SHEET to enrich its content to empower the reader. This column contains the opinions and thoughts of its author and are not necessarily those of Us TOO InternaƟonal.
word "ship" but replace the "p" with a "t") or it also sounds like a tabloid oncology newsletter title that will reveal the latest scandals and affairs! Man that would be fun but simultaneously boring to read. "Prostate cancer researcher gets a divorce and dates 23 year old, or prostate cancer clinician arrested for smoking pot outside of Colorado…." Ahh think of the possibilities Tom Kirk and Us TOO -you could make a fortune! I digressed for a moment, and in reality the cover of the last issue of the Hot SHEET was about the new impressive research on aspirin as a potenƟal way of reducing cancer recurrence (not definiƟve proof but one of the longest studies ever to look at this issue) or reducing the risk of lethal prostate cancer! I will not review this data again but as important as any posiƟve aspirin arƟcle you will ever see it must be kept in mind that whether or not the benefits of taking aspirin (reduces heart aƩacks, stroke, colon cancer, maybe prostate cancer progression) outweigh the negaƟve (ulcers, internal bleeding, need for transfusion, kidney damage). So, everyone reading this column, and I mean everyone, has to go to the new and arguably best questionnaire and calculator ever invented to help you determine if you might need an aspirin and/or statin if you are otherwise healthy (it assumes you have not had a heart attack or stroke). I tell prostate cancer patients to go to this website everyday and calculate their 10-year risk of heart disease or stroke: www.cvriskcalculator.com. It takes seconds. Then discuss it with your doctor to see if the benefits of taking aspirin and/ or a statin outweigh the negative (calculator is for men and women). The site asks you to enter the following: age, gender, race, total cholesterol, HDL cholesterol, systolic and diastolic blood pressure, whether you are being treat-PAGE 3 ed for high blood pressure, whether or not you have diabetes, and smoking status and that is all! DONE!!! For example, the site says that I (Mark Moyad) would not qualify for an aspirin or statin, but in the future I might (the higher the percentage risk the greater the chance you qualify). Regardless, this is the first step toward figuring out if you need aspirin after being treated for prostate cancer because you want to base this decision on your cardiovascular risk (so you can get a two-for-one so to speak). To compare the incidence of infective complications after transrectal ultrasonography (TRUS)-guided biopsy with empirical fluoroquinolone (FQ) or culture-based targeted antimicrobial prophylaxis, and the prevalence of FQ resistance (FQ-R) in men undergoing prostate biopsy. A systematic review of the literature was performed following Preferred Reporting Items for Systematic Reviews and Meta -Analyses (PRISMA) guidelines. We included studies of men undergoing TRUS-guided biopsy that compared infective outcomes of those who received targeted antimicrobial therapy based on the results of pre-procedural rectal swab cultures, with those receiving empiric FQ prophylaxis. The prevalence of FQ-R was recorded as a secondary outcome measure. Studies with no control group were excluded. Of 125 studies screened, nine studies (4,571 men) met the inclusion criteria. All studies were of cohort design, and included a combination of retrospective and prospective data. Six were undertaken in North America. The remaining studies were undertaken in Spain, Turkey and Columbia. Within these studies, 2,484 (54.3%) men received empirical FQ prophylaxis, whilst 2,087 (45.7%) had pre-biopsy rectal swabs and targeted antibiotics. The mean FQ-R was 22.8%. Postbiopsy infection and sepsis rates were significantly higher in groups given empirical FQ prophylaxis (4.55% and 2.21%) compared with groups receiving targeted antibiotics (0.72% and 0.48%). Based on these results 27 men would need to receive targeted antibiotics to prevent one infective complication. Our systematic review suggests that targeted prophylactic antimicrobial therapy before TRUSguided prostate biopsy is associated with lower rates of sepsis. We therefore recommend changing current pathways to adopt this measure.
period were offered openlabel ENZ at the discretion of the patient and study investigator. Findings: Between March 22, 2011, and July 11, 2013, 375 men were randomly assigned, 184 (49%) to ENZ and 191 (51%) evidence includes another recent single-center study (from Italy), which, like the Swedish study, did not find a Ɵe between ED drugs and cancer recurrence (Eur Urol, Vol. 68, pp. 750-753). However, Dr. Schlomm, who was also an investigator on the Swedish study, defended the German study, which was conducted at the MartiniClinic -one of the biggest prostate cancer clinics in the world. "We believe that the differences between our initial data are mainly based on the different patient cohorts," he stated. In the German study, which only included men who underwent surgery, the majority of patients had an organ-defined disease. "We believe that a small biological effect (for example, from PDE5i) can be more likely detected in men with a more favorable overall prognosis than in men with a more aggressive tumor," Dr. Schlomm explained. In the Sweden study, the mix of Background: Enzalutamide (ENZ) is an oral androgenreceptor inhibitor that was shown to improve survival in two placebo-controlled phase 3 trials, and is approved for men with metastaƟc castraƟon-resistant prostate cancer (mCRPC). The objecƟve of the TERRAIN study was to compare the efficacy and safety of ENZ with bicalutamide (CAS) in men with mCRPC. Methods: TERRAIN was a double-blind, randomised phase 2 study, that recruited asymptomatic or minimally symptomatic men with prostate cancer progression on androgen-deprivation therapy (ADT) from academic, community, and private healthcare provision sites across North America and Europe. Eligible men were randomly assigned (1:1) via an interactive voice response system to receive ENZ 160 mg/day or CAS 50 mg/day, both taken orally, in addition to ADT, until disease progression. Men were stratified by a permutated block method (block size of four), by whether bilateral orchiectomy or receipt of luteinizing hormone-releasing hormone agonist; or antagonist therapy started before or after the diagnosis of metastases, and by study site. Patients, investigators, and those assessing outcomes were masked to group assignment. The primary endpoint was progression-free survival (PFS), analyzed in all randomized patients. Safety outcomes were analyzed in all men who received at least one dose of study drug. The open-label period of the trial is in progress, wherein men still on treatment at the end of the double-blind treatment months This prospective pilot study evaluated the ability of sodium fluoride (Na 18 F) positron emission tomography/ computed tomography (NaF-PET/CT) to detect and monitor bone metastases over time and its correlation with clinical outcomes and survival in advanced prostate cancer. PaƟents and Methods: Sixty prostate cancer paƟents, including 30 with and 30 without known bone metastases by convenƟonal imaging underwent NaF-PET/CT at baseline, six, and 12 months. PosiƟve lesions were verified on follow-up scans. Changes in standardized uptake values (SUV) and lesion number were correlated with prostate-specific anƟgen (PSA) change, clinical impression, and overall survival (OS). Results: Sixty paƟents underwent 170 NaF-PET/CT scans. Significant associaƟons included SUV and PSA percent change at 6 (P = 0.014) and 12 months (P = 0.0005); SUV maximal percent change from baseline and clinical impression at six months (P = 0.0147) and six-12 months (P = 0.0053); SUV change at six months and OS (P = 0.018); number of lesions on NaF-PET/CT and clinical impression at baseline (P <0.0001), six (P = 0.0078), and 12 months (P = 0.0029); number of lesions on NaF-PET/CT per paƟent at baseline and OS (P = 0.017). In an exploratory analysis, paired ( 99 m)Tc-MDP bone scans (TcBS) were available in 35 paƟents at baseline, 19 at six months, and 14 at 12 months (n = 68 scans). Malignant lesions on NaF-PET/CT (n =57) were classified on TcBS as malignant 65%; indeterminate 25%; and negaƟve 10%. AddiƟon-ally 65% of paired scans showed more lesions on NaF-PET/CT than on TcBS. Conclusions: Baseline number of malignant lesions and changes in SUV on follow-up NaF-PET/CT significantly correlates with clinical impression and OS. NaF-PET/CT detects more bone metastases earlier than TcBS and enhances detecƟon of new bone disease in high-risk paƟents.
and/or volume reclassificaƟon, which was the primary study end point. Men were "reclassified" on the basis of two measures: increased Gleason grade (primary or sum); and greater tumor volume (a raƟo of posiƟve to total number of cores; where a raƟo below or above 34% indicaƟves stability or an increase, respecƟvely). InvesƟgators prefer the term reclassificaƟon over progression because undersampling at diagnosis can explain why a more serious prostate cancer is not detected iniƟally. Notably, many men offered treatment did not jump at the opportunity. Of 216 men reclassified , 83 (38%) remained on AS or were considering treatment. Another 115 (53%) underwent definitive treatment and 18 dropped out of PASS without confirmed treatment. Of the 689 men who did not undergo disease reclassification, 560 remained on AS, 55 opted for treatment, and 74 dropped out. "The dropout rate in the Canary PASS study appears to be higher than at least one of the pioneering centers. Only 2.5% of men in the Sunnybrook (Toronto) cohort have been lost to follow-up," principal investigator Lawrence Klotz, MD said in 2014. In the Canary PASS study, the probability of a man remaining on AS two years after diagnosis was 88%; five and 10 years post-diagnosis, 71% and 50% of men remained on AS, respectively, according to Kaplan-Meier estimates. Overall, of the men who underwent RP aŌer a period of AS, 34 (33%) were pathologically upgraded at RP and 14 (14%) were downgraded. A total of 35 men (34%) had adverse pathologic features at RP, including a primary Gleason paƩern of 4 or 5, extraprostaƟc extension, seminal vesicle invasion, or lymph node metastasis. "This is real-world AS. It's very important to have this dataset," said Alexander KuƟkov, MD, a urologist from the Fox Chase Cancer Center in Philadelphia, PA, who was asked for comment and was not involved with the research. He pointed out that a majority of the Canary PASS sites are major academic cancer centers. InvesƟgators emphasized, "Importantly, there was no significant relaƟonship between risk classificaƟon (very low, low, and intermediate) at diagnosis and adverse pathology at surgery." Specifically, the percentage of men who, aŌer a period of being watched, had adverse pathology at RP was similar in the three risk categories; 37% were classified as verylow risk at diagnosis, 32% as low-risk, and 40% as intermediate-or high-risk. This finding was the biggest "takeaway" for Dr. KuƟkov. "NCCN risk straƟficaƟon didn't really correlate with adverse pathology [at RP]," he said. "In this study, it didn't maƩer what your risk group was." The clinical factors associated with reclassificaƟon were "weak" or "modest," Dr. Lin pointed out. "Clinical factors cannot adequately predict who will progress," he said. However, the study did show that PSA density, tumor volume, and body mass index "do seem to have a modest associaƟon with grade progression." "A more biologically based assessment of risk at diagnosis, as well as during periodic re-evaluaƟon, is needed," Dr. Lin said. "It's up to us to find beƩer markers," he added.
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S9346 trial who had no private insurance with their Medicare claims to invesƟ-gate differences in long-term adverse events. The adverse events were grouped into five categories: endocrine events, sexual dysfuncƟon, demenƟa and depression, acute kidney injury, and ischemia and thrombosis. For the first four categories, there was no significant difference between groups. But the 10-year cumulaƟve incidence of ischemic and thromboƟc events differed significantly; it was 24% in the cADT group and 33% in the iADT group (hazard raƟo, 0.69; P = 0.02). The men had a median age of 71 years and overall, had a lot of health issues. "The reality is that long-term, health-related events were high in both arms," said Dr. Hershman. The most common long-term events were hypercholesterolemia (31%) and osteoporosis (19%). Dr. Hershman also observed that all of the men in the study received ADT prior to randomizaƟon. "Therefore, the benefits of iADT on chronic complicaƟons may be limited," she said, explaining the unexpected results. A pair of Canadian experts, Saroj Niraula, MBBS, MD, from the University of Manitoba in Winnipeg, and Ian F. Tannock, MD, PhD, from the University of Toronto, wrote an accompanying editorial. The findings are weakened by "methodological limitaƟons," they stated. "Neither the primary SWOG study nor the current one was powered adequately to examine differences in occurrence of toxic effects between the two strategies. Thus, the study does not prove the staƟsƟcal superiority of cADT in terms of thromboembolic and ischemic events. However, the pair acknowledged that, given the direcƟon of this trend, "it is highly unlikely that a larger RCT would find [the events] to be reduced with iADT." Editorialists and the study authors speculate as to why there were more ischemic and thromboƟc events with iADT. The authors call the result "counterintuiƟve." Among other thoughts, the editorialists said: "MulƟple insults to the coagulaƟon system with decrease and increase in testosterone levels during iADT might therefore be responsible for the observaƟons in the study." The authors touch on that same idea: "Changes in the coagulation cascade have been reported with lowering of testosterone during ADT as well as with increasing estrogen (after stopping ADT)." The authors conclude that iADT is something that clinicians should be "cauƟous" about using in elderly men with metastaƟc prostate cancer. They added that more study is needed in this area. But the editorialists provide a slightly different summary, which accents the posiƟve. Any advantage of iADT is likely to be limited to possible improvements in QOL parƟcularly during the offtreatment period; convenience of therapy; and savings in cost.
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non-randomized study. Regardless, their findings were that targeted anƟbioƟc therapy had a lower incidence of infecƟons compared to using untargeted fluoroquinolones. However, they found that 27 men would need targeted therapy to prevent one infecƟon. That is likely to substanƟally increase the costs, although a full cost analysis of treaƟng infecƟons that occur without targeted therapy would likely make this approach more cost effecƟve. More data would help to change the standard approach to using rouƟne rectal swabs a targeƟng the prophylaxis. The BoƩom Line: Rectal swabs and targeted anƟbioƟc therapy appear to offer a more effecƟve approach to prevenƟng infecƟons following prostate biopsy but more data are needed to make it the standard of care.
The Bottom Line
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A study presented at the 2016 Genitourinary Cancers Symposium (GuS) showed that 40% of paƟents with metastaƟc castraƟon-resistant prostate cancer treated with docetaxel following abiraterone (ZyƟga®) had at least a 50% reducƟon in PSA, demonstraƟng the acƟvity of this drug sequencing. These findings were presented at the Genitourinary Cancers Symposium (GuS) by Thomas W. Flaig, MD, of the University of Colorado Cancer Center, and colleagues. The mulƟ-insƟtuƟon study followed 1,088 men treated on the clinical trial COU-AA-302. Of those treated with abiraterone, 67% went on to receive further therapies, with 36% receiving two addiƟonal therapies and 17% receiving three or more. About half of all abirateronetreated men on the study were treated with docetaxel in the next line of therapy.
Of the men receiving docetaxel aŌer abiraterone, 40% had PSA decline by more than half, demonstraƟng the effecƟveness of this chemotherapy even aŌer treatment with androgen-deprivaƟon therapy.
"Surprisingly, the next most common 'treatment' aŌer docetaxel in this seƫng was no treatment at all," Dr. 
